Who is set to be the winners in medtech as we close in on the fourth industrial revolution? Will technology help deliver affordable, personal healthcare or will outside factors from political to organisational stop innovation from reaching its potential benefit? Whilst early stage companies must look for ways to mitigate against potential risks, they must also grasp every opportunity open to them to disrupt their market.
Who are the active investors in healthcare? What are their aims and how do they approach and consider new investments? How do they work together and how can their different strategies sometimes pit them against each other? This opening panel session looks at the different type of investors, what motivates them and how they are adapting in a changing marketplace.
- Qualifying the demand for your device, is this the most important thing?
- Do companies and investors tend to over promise (and is that always a bad thing)?
- ROI and time commitment, are these investors main considerations?
A honest and open interview with a CEO who has successfully built a healthcare business in the Gulf region, one of the most exciting of the emerging markets in medical devices. Lina will discuss how success has been built from her company’s innovative structure, philosophy and ability to add value in many different ways.
Tissot Medical is an ophthalmic device company founded in 2010 by serial medical technology entrepreneur Luc Tissot of the famed Swiss watch-making family. Tissot Medical Research have taken Swiss technological expertise and are advancing eye care through mHealth enabled ophthalmic devices.
These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes.
With a changing healthcare market that is seeing traditional success formulas being redefined, how should companies and investors adapt their strategies to be successful? Strong management and sustainable and unique competitive advantage has always been vital, how is market access and value (in all its terms) now fitting into the mix as well?
- How can you disrupt white spaces?
- Are emerging markets a battleground or a cemetery?
- Is simplicity and strength more important than complexity and scale?
Special pre-scheduled individual One-To-One meetings will be taking place in our dedicated meeting area. This session will consist of 4 x 20min One-To-One meetings.
This will be an informal reception allowing you to network with all attendees